EARLY LABORATORY INDICATORS OF RENAL INVOLVEMENT IN POLYANGIITIS GRANULOMATOSIS WITH RHINOSINUSITIS
DOI:
https://doi.org/10.57231/j.ejohns.2025.4.4.009Keywords:
granulomatosis with polyangiitis, rhinosinusitis, urinary syndrome, microhaematuria, proteinuria, renal involvement, urinalysis, early diagnosisAbstract
To evaluate the role of urinary syndrome as an early laboratory marker of renal involvement in patients with
granulomatosis with polyangiitis (GPA) presenting with rhinosinusitis. The study included GPA patients with dominant
ENT manifestations and a control group with isolated chronic rhinosinusitis. All participants underwent routine urinalysis;
urine volume, speci# c gravity, pH, leukocyturia, erythrocyturia and proteinuria were analysed in relation to disease
stage and treatment. In the # rst and second GPA groups, asymptomatic microhaematuria, low-grade proteinuria and
leukocyturia were detected in the majority of patients, indicating subclinical glomerular injury long before the onset of
overt nephritic symptoms. After immunosuppressive therapy, urinary parameters in the third group almost normalized,
con# rming the reversibility of early changes. Simple urinalysis with careful interpretation of minimal urinary abnormalities
therefore provides a cheap and sensitive tool for early detection of renal involvement in GPA-related rhinosinusitis and
for timely referral to nephrology
References
Wang R, Wang J, Hu Y, et al. Clinicopathological characteristics and outcomes of anti-neutrophil cytoplasmic antibody-associated vasculitis with acute kidney involvement. Sci Rep. 2021;11.
Wang R, Liu Y, Li X, et al. Hyperuricemia has an important in$ uence on the progression of ANCA-associated renal vasculitis. Sci Rep. 2021;11.
Haraziński P, Piskorz F, Krzanowska K, et al. Granulomatosis with polyangiitis presenting with kidney failure: a case report. Cureus. 2025;17(1).
Marvisi C, Arioli D, Gallelli L, et al. Biomarkers in ANCAassociated vasculitis: clinical utility, pitfalls and their role in the outcomes assessment. Front Immunol. 2025;16:1616837.
Horai Y, Fujimoto S, Amano K, et al. Current diagnosis and treatment of anti-neutrophil cytoplasmic antibodyassociated
vasculitis. J Clin Med. 2025;14(5):1724.
Geetha D, Dua A, Yue H, et al. Effi cacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomized trial. Ann Rheum Dis. 2024;83(2):223–232.
Jayne DRW, Merkel PA, Schall TJ, Bekker P; ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384:599–609.
Stacey SD, Holle J, Little MA, et al. Practical management of ANCA-associated vasculitis. Clin Med (Lond). 2024;24(5).
Delvino P, La Rocca G, et al. Systemic vasculitis: one year in review 2025. Clin Exp Rheumatol. 2025;43(Suppl.).
Hunter RW, Welsh N, Farrah TE, Gallacher PJ. ANCAassociated vasculitis. BMJ. 2020;369:m1070.
Wang R, Liu Y, Li X, et al. Long-term outcomes and prognostic factors for survival of patients with ANCAassociated vasculitis. Nephrol Dial Transplant. 2022;37(10).
King C, Harper L. Small vessel vasculitides: an update. Autoimmun Rev. 2024;23(8):103429.
Morales E, Martínez-Morillo M, et al. Recommendations for the diagnosis and treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis. Nefrologia. 2025;45(3).
